¼¼°èÀÇ ¾ÏÄ¡·á ½ÃÀå
Cancer Therapies
»óǰÄÚµå : 1760844
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 590 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,106,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,320,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¾ÏÄ¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 3,820¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 2,105¾ï ´Þ·¯·Î ÃßÁ¤µÇÁö¸¸ Ä¡·á ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 10.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 3,820¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Ç÷¾×¾ÏÀº CAGR 12.2%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1,192¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯¹æ¾Ï ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 9.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 825¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR12.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¾ÏÄ¡·á ½ÃÀåÀº 2024³â¿¡ 825¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 353¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.9%·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 7.0%¿Í 7.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.6%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¾ÏÄ¡·á ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¾Ï Ä¡·á´Â Áö³­ ¼ö½Ê³âµ¿¾È Å©°Ô ¹ßÀüÇÏ¿© ȯÀÚÀÇ ¿¹ÈÄ¿Í »ýÁ¸À²À» Çâ»ó½ÃÄ×½À´Ï´Ù. ¾Ï Ä¡·á´Â È­Çпä¹ý, ºÐÀÚ Ç¥Àû Ä¡·á, ¹æ»ç¼± Ä¡·á, ¸é¿ª ¿ä¹ý µîÀ» ÅëÇØ ¾Ï ȯÀÚ¸¦ Ä¡·áÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á´Â ¾Ï¼¼Æ÷¸¦ Á¦°ÅÇϰųª ÆÄ±«ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¼ö¼úÀº Á¾¾çÀ» ¹°¸®ÀûÀ¸·Î ÀýÁ¦Çϰí, È­Çпä¹ýÀº °­·ÂÇÑ ¾à¹°À» »ç¿ëÇÏ¿© ºü¸£°Ô ºÐ¿­ÇÏ´Â ¼¼Æ÷¸¦ Á×À̰í, ¹æ»ç¼± ¿ä¹ýÀº °í¿¡³ÊÁö ¹æ»ç¼±À» »ç¿ëÇÏ¿© ¾Ï¼¼Æ÷ÀÇ DNA¿¡ ¼Õ»óÀ» ÁÖ¾î Áõ½ÄÀ» ¸·´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¿¡´Â ºÎÀÛ¿ëÀÌ µû¸£±â ¶§¹®¿¡ º¸´Ù Ç¥ÀûÀ» Á¼È÷°í ´ú ÇØ·Î¿î Ä¡·á¹ýÀ» °è¼Ó ã°í ÀÖ½À´Ï´Ù.

ÃÖ±Ù ¾Ï Ä¡·áÀÇ ¹ßÀüÀº °Ç°­ÇÑ Á¶Á÷À» º¸Á¸Çϸ鼭 ¾Ï¼¼Æ÷¸¦ ƯÀÌÀûÀ¸·Î Ç¥ÀûÀ¸·Î »ï´Â Ä¡·á¿¡ ÃÊÁ¡À» ¸ÂÃá Á¤¹ÐÀÇ·áÀÇ »õ·Î¿î ½Ã´ë¸¦ ¿­¾ú½À´Ï´Ù. ½ÅüÀÇ ¸é¿ªÃ¼°è¸¦ Ȱ¿ëÇÏ¿© ¾Ï°ú ½Î¿ì´Â ¸é¿ª¿ä¹ýÀº ´Ù¾çÇÑ À¯ÇüÀÇ ¾Ï Ä¡·á¿¡¼­ °ý¸ñÇÒ ¸¸ÇÑ ¼º°øÀ» °ÅµÎ°í ÀÖ½À´Ï´Ù. üũÆ÷ÀÎÆ® ¾ïÁ¦Á¦, CAR-T ¼¼Æ÷Ä¡·áÁ¦, ¾Ï ¹é½ÅÀº ÃÖ±Ù ½ÂÀÎµÈ Çõ½ÅÀûÀÎ ¸é¿ªÄ¡·á Á¢±Ù¹ý Áß ÀϺÎÀÔ´Ï´Ù. ¶ÇÇÑ, Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦, ´ÜÀÏŬ·ÐÇ×ü µî ¾ÏÀÇ Áõ½Ä°ú ÁøÇà¿¡ °ü¿©Çϴ ƯÁ¤ ºÐÀÚ¸¦ ¾ïÁ¦Çϴ ǥÀûÄ¡·áÁ¦´Â ±âÁ¸ ¹æ½Ä¿¡ ºñÇØ ºÎÀÛ¿ëÀÌ Àû°í È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ȯÀÚÀÇ Á¾¾ç À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á¹ýÀ» Á¶Á¤ÇÏ´Â ¸ÂÃãÀÇ·áÀÇ µîÀåÀº ¾Ï Ä¡·áÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀ» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.

¾Ï Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ¹× À¯ÀüüÇÐÀÇ ¹ßÀüÀ¸·Î »õ·Î¿î Ä¡·á¹ý°ú °³ÀÎ ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ýÀÌ °³¹ßµÇ¾î ȯÀÚ°¡ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¼±ÅÃÀÇ ÆøÀÌ Å©°Ô ³Ð¾îÁ³½À´Ï´Ù. Àα¸ °í·ÉÈ­¿Í »ýȰ½À°üÀÇ ¿µÇâÀ¸·Î Àü ¼¼°èÀûÀ¸·Î ¾ÏÀÇ À¯º´·üÀÌ Áõ°¡Çϸ鼭 È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾àȸ»ç¿Í Á¤ºÎ±â°üÀÇ ¾Ï ¿¬±¸¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ·Î »õ·Î¿î Ä¡·á¹ýÀÇ ¹ß°ß°ú °³¹ßÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Ï¿¡ ´ëÇÑ Àνİú Á¶±â Áø´Ü¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¶±â ¾ÏÀº ÃֽŠġ·á¹ýÀ¸·Î ´õ ½±°Ô Ä¡·áÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ´ç±¹ÀÇ »õ·Î¿î Çõ½ÅÀû Ä¡·á¹ý ½ÂÀÎÀº ȯÀÚ¿Í ÀÓ»óÀÇ¿¡°Ô ´õ ¸¹Àº ¼±ÅñÇÀ» Á¦°øÇÕ´Ï´Ù. ƯÈ÷ ½ÅÈï±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®ÃæÀº ´õ ¸¹Àº »ç¶÷µéÀÌ Ã·´Ü ¾Ï Ä¡·á¹ýÀ» ´õ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ±â¾÷, ¿¬±¸±â°ü, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü °£ÀÇ Çù·Â°ú ÆÄÆ®³Ê½ÊÀº Çõ½ÅÀ» ÃËÁøÇϰí ÷´Ü ¾Ï Ä¡·á¹ýÀÇ »ó¿ëÈ­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á À¯Çü(È­Çпä¹ý, Ç¥ÀûÄ¡·á, ¸é¿ªÄ¡·á, È£¸£¸ó ¿ä¹ý, ±âŸ Ä¡·á À¯Çü), ¾Ï À¯Çü(Ç÷¾×¾Ï, À¯¹æ¾Ï, Àü¸³¼±¾Ï, ¼ÒÈ­±â¾Ï, ºÎÀΰú¾Ï, Æó¾Ï, ±âŸ ¾Ï À¯Çü)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 109°³»ç)

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå°ú °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cancer Therapies Market to Reach US$382.0 Billion by 2030

The global market for Cancer Therapies estimated at US$210.5 Billion in the year 2024, is expected to reach US$382.0 Billion by 2030, growing at a CAGR of 10.4% over the analysis period 2024-2030. Blood Cancer, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$119.2 Billion by the end of the analysis period. Growth in the Breast Cancer segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$82.5 Billion While China is Forecast to Grow at 12.9% CAGR

The Cancer Therapies market in the U.S. is estimated at US$82.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$35.3 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Global Cancer Therapies Market - Key Trends & Drivers Summarized

Cancer therapies have evolved significantly over the past few decades, leading to improved patient outcomes and survival rates. Cancer therapy refers to the treatment of a patient suffering from cancer with therapies such as chemotherapy, targeted therapy, radiation therapy and immunotherapy among others. These treatments target the removal or destruction of cancerous cells. Surgery involves physically removing tumors, while chemotherapy uses potent drugs to kill rapidly dividing cells, and radiation therapy employs high-energy radiation to damage DNA in cancer cells, preventing them from multiplying. Given the side effects associated with these treatments, there has been a continuous search for more targeted and less harmful treatment options.

Recent advancements in cancer therapies have introduced a new era of precision medicine, focusing on treatments that specifically target cancer cells while sparing healthy tissue. Immunotherapy, which leverages the body's immune system to fight cancer, has shown remarkable success in treating various types of cancer. Checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are some of the innovative immunotherapy approaches that have gained approval in recent years. Additionally, targeted therapies that interfere with specific molecules involved in cancer growth and progression, such as tyrosine kinase inhibitors and monoclonal antibodies, have provided effective treatment options with fewer side effects compared to traditional methods. The advent of personalized medicine, where treatments are tailored based on the genetic profile of the patient’s tumor, has further enhanced the efficacy and safety of cancer therapies.

The growth in the cancer therapies market is driven by several factors. Advances in biotechnology and genomics have led to the development of novel therapies and personalized treatment approaches, significantly expanding the range of options available to patients. The increasing prevalence of cancer worldwide, partly due to aging populations and lifestyle factors, is fueling demand for effective treatments. Moreover, substantial investment in cancer research by pharmaceutical companies and government agencies is accelerating the discovery and development of new therapies. The rising awareness and early diagnosis of cancer are also contributing to market growth, as early-stage cancers are more treatable with modern therapies. Additionally, regulatory approvals of new and innovative treatments are providing more options for patients and clinicians. The expansion of healthcare infrastructure, particularly in emerging economies, is making advanced cancer therapies more accessible to a broader population. Collaborations and partnerships among biotech firms, research institutions, and healthcare providers are fostering innovation and facilitating the commercialization of cutting-edge cancer treatments.

SCOPE OF STUDY:

The report analyzes the Cancer Therapies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Other Treatment Types); Cancer Type (Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Other Cancer Types)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 109 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â